It is estimated that every 27 seconds, someone in the U.S. attempts suicide. The risk of Acute Suicidal Ideation and Behavior, or ASIB, is uniquely high in patients during bipolar depressive episodes, compared to those with major depressive disorder, thought disorders, and personality disorders. Between 11% to 20% of individuals diagnosed with bipolar disorder will ultimately succumb to suicide, according to reports.
The stock we are bringing to your attention today is that of NRx Pharmaceuticals Inc. (NRXP), which is developing a drug for suicidal treatment-resistant bipolar depression.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com